PMDA drug package insert
セルトラリン錠25mg「杏林」
PMDA Prescription drug · キョーリンリメディオ株式会社 · package insert May 30, 2024
Key facts
| Brand names | セルトラリン錠25mg「杏林」, セルトラリン錠50mg「杏林」, セルトラリン錠100mg「杏林」 |
|---|---|
| Nonproprietary names | セルトラリン塩酸塩 |
| Companies | 製造販売元／キョーリンリメディオ株式会社, 販売元／杏林製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 選択的セロトニン再取り込み阻害剤 |
| Therapeutic category codes | 871179 |
| YJ codes | 1179046F1095, 1179046F2091, 1179046F3128 |
| Approval numbers | 22700AMX00944000, 22700AMX00945000, 22800AMX00300000 |
| Package insert edition | 第5版 |
| Package insert date | May 30, 2024 |
| PMDA document key | 480209_1179046F1095_1 |
| PMDA company code | 480209 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: